# NorthStar Medical Technologies

> Radiopharmaceutical infrastructure company producing medical radioisotopes and providing clinical and commercial drug-manufacturing services.

## Why it is interesting

NorthStar is building supply-chain infrastructure for radiopharmaceutical oncology, where limited availability of isotopes such as actinium-225 can constrain clinical trials and commercial deployment.

## Profile

- **Latest funding:** Not publicly disclosed
- **Latest known valuation:** Not publicly disclosed
- **Total disclosed equity funding:** Not publicly disclosed
- **Stage:** growth
- **Status:** private
- **Industries:** healthtech, biotech-life-sciences, deep-tech
- **Coverage:** full
- **Last updated:** 2026-10-04

## Key facts

- Announced a multi-year growth-capital facility of up to $185 million from Hercules Capital on September 29, 2026, including $100 million funded upfront.
- Company says it routinely produces no-carrier-added actinium-225 at commercial scale using electron accelerators.
- Operates co-located isotope-production and radiopharmaceutical CDMO infrastructure in Beloit, Wisconsin.

## Funding history

- Growth capital facility / venture debt · Up to $185 million; $100 million funded upfront · September 29, 2026
  Source: https://www.northstarnm.com/northstar-secures-growth-financing/

## Investors in our directory

- https://venturecapitaltracker.com/fund/hercules-capital

## Related articles

- https://venturecapitaltracker.com/2026-northstar-medical-185m-hercules-growth-facility

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)
**Last updated:** October 4, 2026

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.

---
Source: https://venturecapitaltracker.com/startup/northstar-medical-technologies